Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 3/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4452290 | 0.79 | KDM1A (0.42) | ALDH1A1CYP2C19GAACES2MAPT | |
| SCHEMBL29074086 | 0.78 | AKR1C3 (0.57) | ALDH1A1CYP2C19SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4862898 | 0.77 | CES2 (0.44) | ALDH1A1CES1CES2MAPTRAB9A | |
| SCHEMBL5469786 | 0.77 | CES2 (0.44) | ALDH1A1MAPK1GAATSHRCES1 | |
| SCHEMBL5464455 | 0.77 | ALDH1A1 (0.45) | ALDH1A1TDP1MAPK1GAACES1 | |
| SCHEMBL7093240 | 0.77 | KMT2A (0.48) | ALDH1A1TDP1MAPK1CYP2C19TSHR | |
| SCHEMBL12858417 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPK1CYP2C19GAA | |
| SCHEMBL27910238 | 0.76 | AKT1 (0.48) | ALDH1A1TDP1MAPK1CYP2C19GAA | |
| SCHEMBL6058836 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPK1CYP2C19GAA | |
| SCHEMBL6058838 | 0.76 | ALDH1A1 (0.50) | ALDH1A1TDP1MAPK1CYP2C19GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276506-B2 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1663244-B1 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF TNF-ALPHA-RELATED DISEASES. | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | 4 AZA BIOSCIENCE NV (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2006-08-24 | — | — | US | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1663244-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-ALPHA-RELATED DISEASES. | 4 AZA Bioscience nv (BE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005025574-A2 | PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK AND TNF-α-RELATED DISEASES. | 4 AZA BIOSCIENCE NV (BE) | 2005-03-24 | — | — | WO | disclosed |
| EP-1144412-B1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | 4 AZA BIOSCIENCE NV (BE) | 2004-09-29 | — | — | EP | disclosed |
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | 4 AZA BIOSCIENCE NV (BE) | 2004-04-22 | — | — | US | disclosed |
| EP-1144412-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. Leuven Research & Development (BE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000039129-A1 | IMMUNOSUPPRESSIVE EFFECTS OF PTERIDINE DERIVATIVES | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2000-07-06 | — | — | WO | disclosed |
| US-4032659-A | ADMINISTERING THIOSEMICARBAZONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-06-28 | — | — | US | disclosed |
| US-4027039-A | ADMINISTERING AMINOGUANIDINE, GUANIDINE, OR 1-(SEC-BUTYLIDENEAMINO)GUANIDINE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
| US-3980774-A | HYDRAZINE AND HYDRAZINE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077859-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | ALDH1A1 1257/4885TDP1 820/4885MAPK1 2381/4885 |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | ALDH1A1 1733/4885TDP1 469/4885MAPK1 2887/4885 |
| US-20060189620-A1 | Immunosuppressive effects of pteridine derivatives | TPMT, NFATC1, MALT1 | ALDH1A1 1257/4885TDP1 820/4885MAPK1 2381/4885 |
| US-20070004721-A1 | Pteridine derivatives for the treatment of septic shock and tnf-a-related diseases | TNF, TNFRSF1A, TLR4 | ALDH1A1 3134/4885TDP1 1505/4885MAPK1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.